Skip to main content

LianBio

LIANY
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001831283

No open-market purchases or sales by LianBio insiders were filed in the last 90 days; 1 institution reported holding it in 13F filings for Q2 2026, worth $1.00K in total; no superinvestor holds it.

Holders of 5% or more of LIANY

Holders whose latest Schedule 13D or 13G filing reports 5% or more of LianBio, largest stake first. The change is against the holder's previous filing.

No holder currently reports owning 5% or more of LianBio on Schedule 13D or 13G.

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

5 Schedule 13D and 13G filings on LianBio, newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on LIANY
Filed (ET)FilerFormStakeChangeEvent dateFiling
Feb 14, 2023Venrock Healthcare Capital Partners II, L.P.13G/AOld format–––SEC
Nov 14, 2022Ra Capital Management, L.P.13G/AOld format–––SEC
Nov 15, 2021Perceptive Advisors LLC13DOld format–New–SEC
Nov 15, 2021Ra Capital Management, L.P.13GOld format–New–SEC
Nov 10, 2021Venrock Healthcare Capital Partners II, L.P.13GOld format–New–SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell LianBio shares.

No Form 144 notices for LianBio are on file.